Third Party Vendors and Service Providers. The Parties acknowledge that Novartis and its Affiliates will not transfer or assign any agreements that it or they may have with vendors or service providers (e.g., contract research organizations, contract clinical trial sites, consultants, etc.) in connection with the transactions contemplated by this Agreement. To the extent that Company proposes to engage one or more of such vendors and service providers in connection with the Development or Commercialization of an Antibody or Product after the Effective Date, at Company’s written request, Novartis will provide reasonable assistance to Company in such efforts by issuing a letter of authorization to enable Company to request access to or copies of any information or documents identified in Exhibit B from any such vendor or service provider, solely to the extent related to the applicable Antibody or Product held by such vendors or service providers, at Company’s sole cost and expense and pursuant to a separate agreement to be entered into between Company and any such vendors or service providers. Confidential Treatment Requested by Xxxx Therapeutics, Inc. Pursuant to 17 C.F.R. § 200.83 5. DEVELOPMENT; REGULATORY
Third Party Vendors and Service Providers. The Parties acknowledge that Novartis and its Affiliates will not transfer or assign any agreements that it or they may have with vendors or service providers (e.g., contract research organizations, contract manufacturers, contract clinical trial sites, consultants, etc.), in connection with the license set forth in this Agreement. However, to the extent that Erasca intends to engage one or more of such vendors and service providers in connection with its own efforts to Develop or Commercialize the Licensed Compound or Licensed Products, at Erasca’s written request, Novartis will issue a letter of authorization, within [***] after written request by Xxxxxx, to enable Erasca to request access to or copies of any information and data related to the Licensed Compound or Licensed Products held by Novartis’ vendors or service providers, at Erasca’s sole cost and expense and pursuant to separate agreements to be negotiated and executed between Erasca and such vendors or service providers.
Third Party Vendors and Service Providers. The Parties acknowledge that Novartis and its Affiliates will not transfer or assign any agreements that it or they may have with vendors or service providers (e.g., contract research organizations, contract manufacturers, contract clinical trial sites, consultants, etc.) in connection with the license set forth in this Agreement. However, to the extent that Ideaya intends to engage one or more of such vendors and service providers in connection with its own efforts to Develop or Commercialize the Compounds, Products and/or Biomarker/Companion Diagnostics, at Ideaya’s written request, Novartis will issue a letter of authorization to enable Ideaya to request access to or copies of any information and data related to the Compounds, Products and/or Biomarker/Companion Diagnostics held by Novartis’ vendors or service providers, at Ideaya’s sole cost and expense and pursuant to separate agreements to be negotiated and executed between Ideaya and such vendors or service providers. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
